VEGFA and lip and oral cavity carcinoma: Zcharia et al. (2005) reported that high levels of heparanase in wound healing accelerated tissue repair and skin restoration, mediated mainly by an increased angiogenic response. These actions make heparanase a promising target for cancer therapy (Vlodavsky et al., 2018). Monoclonal antibodies against VEGFA were the first angiogenesis inhibitors authorized for the treatment of colon cancer patients with metastasis based on their survival benefit (Hurwitz et al., 2004) and could also be a tool to combat advanced oral cancer disease.